Can You Take Creatine While Pregnant?

No major medical or obstetric organization currently recommends creatine supplementation during pregnancy, and no large clinical trial has tested its safety or effectiveness in pregnant women. That said, this is not a closed question. A growing body of preclinical research, mostly in animal models, suggests creatine could protect the fetal brain and other organs from damage caused by oxygen deprivation during birth, and the first small human pharmacokinetic trial has now been completed with no major adverse events reported. The gap between “promising animal data” and “safe to take during your pregnancy” remains wide, and understanding where the science actually stands matters if you are considering it.

Why Researchers Are Interested in Creatine and Pregnancy

Your body makes creatine on its own and you get more from food, especially red meat and fish. Creatine’s main job is acting as a quick-access energy reserve: it helps cells regenerate the molecule that powers nearly every cellular process, ATP. This energy-buffering role is especially relevant in tissues that experience sudden spikes in energy demand, and few biological events are more energetically demanding than pregnancy and birth.

The placenta, the developing fetal brain, the heart, and the diaphragm all have high or rapidly shifting energy needs. A review of the literature found that the creatine energy circuit is used extensively by tissues in the female reproductive system, the placenta, and the developing fetus throughout pregnancy.¹ This is what makes creatine interesting to researchers studying complications like birth asphyxia, fetal growth restriction, and premature birth. The hypothesis is straightforward: if you load maternal tissues with extra creatine before a stressful birth event, the baby might have a larger energy buffer to ride out periods of oxygen deprivation.

What Changes in Creatine Metabolism During Pregnancy

A prospective cohort study tracking creatine levels across pregnancy found that while plasma creatine in the mother stayed stable from early pregnancy to delivery, urinary creatine dropped significantly in late gestation.² Meanwhile, guanidinoacetate (the precursor your body uses to manufacture creatine) fell in the blood during mid-pregnancy before rising again toward birth. This pattern suggests the mother’s body is working harder to synthesize and retain creatine as pregnancy progresses, likely because demand is increasing as the fetus grows.

The practical implication is that late pregnancy appears to be a period of relative creatine depletion. The mother’s system is diverting resources toward creatine production, and urinary losses decrease as though the body is trying to conserve what it has. Whether supplementation during this window would meaningfully improve outcomes is exactly what researchers are trying to figure out.

The Placenta Can Make Its Own Creatine

One question that matters a great deal is whether creatine from the mother actually reaches the fetus. The answer turns out to be more complicated than expected, and it differs between species.

In humans, the term placenta expresses the genetic machinery needed both to synthesize creatine locally and to transport it. A study examining placentas from eleven term deliveries confirmed that the genes for the key enzymes involved in creatine production, as well as the creatine transporter, were active in all samples.³ This means the human placenta does not just passively shuttle creatine from mother to fetus; it can manufacture creatine on-site, which may be one way the fetus secures its energy supply even if maternal levels fluctuate.

In sheep, however, a study found that raising the mother’s plasma creatine concentration three- to fourfold through infusion did not significantly change creatine levels in fetal blood, amniotic fluid, fetal tissues, or the placenta. The sheep placenta appeared to release the creatine precursor (guanidinoacetate) back into the maternal circulation rather than passing creatine to the fetus.⁴ This species difference is a genuine complication for the field. If simply raising maternal creatine does not reliably increase fetal creatine in all mammals, the mechanism of any protective effect may not be as simple as “more creatine in the mother equals more creatine in the baby.” It could work through other pathways, like improving placental energy reserves or stabilizing the mother’s cardiovascular response to labor.

What Animal Studies Show About Fetal Protection

The most compelling evidence for creatine supplementation in pregnancy comes from the spiny mouse, a small rodent whose developmental biology is closer to humans than the common lab mouse. Multiple studies using this model have tested whether feeding the mother extra creatine before birth protects the offspring from simulated birth asphyxia, and the results have been consistently positive across several organ systems.

In the brain, creatine supplementation reduced markers of oxidative damage and improved blood flow after oxygen deprivation. Researchers have proposed that creatine interacts with a specific receptor in the brain that may counteract the toxic cascade triggered when brain cells are starved of oxygen, offering protection to both preterm and term fetal brains.⁵ The neuroprotective angle is what has drawn the most attention, since birth asphyxia remains a leading cause of death and disability in newborns worldwide, and treatment options after the fact are limited.⁶

The diaphragm, which a newborn needs to start breathing independently at birth, also benefited. In spiny mice exposed to birth asphyxia, maternal creatine supplementation from mid-pregnancy significantly reduced muscle fiber shrinkage, contractile dysfunction, and harmful changes in gene expression in the diaphragm.⁷ In the kidneys, birth asphyxia caused acute injury including shrunken glomeruli, disordered tubules, and elevated injury markers, but maternal creatine supplementation prevented these abnormalities.⁸

These findings are striking because they show protection across multiple organs simultaneously, not just the brain. The argument researchers make is that birth asphyxia is a whole-body event, so a whole-body energy buffer like creatine has an advantage over treatments that target only one organ system.

Long-Term Effects on Offspring

An obvious concern with any supplement given during pregnancy is whether it has unintended consequences for the child’s development down the road. A study in spiny mice tracked offspring behavior from the newborn period through adolescence and adulthood. Pups whose mothers received creatine during pregnancy showed reduced anxiety-like behavior at three days old, which is notable because birth asphyxia normally increases anxiety in these animals. The reduction in anxiety persisted into adolescence. However, creatine-exposed offspring also showed reduced exploration of objects and increased body weight, regardless of whether they had experienced birth asphyxia.⁹

These mixed results deserve attention. The anxiety reduction looks beneficial, but the reduced exploration and weight gain raise questions about whether prenatal creatine exposure has subtle developmental effects that would not show up in a short-term safety study. It is one study in one animal species, so it would be premature to draw firm conclusions. But it illustrates why researchers are cautious about jumping from “it protects against asphyxia” to “everyone should take it.”

The Creatine Pathway in Fetal Growth Restriction

Fetal growth restriction, where the baby is significantly smaller than expected for gestational age, is a condition that involves compromised placental function. Recent research has uncovered something interesting about creatine’s role in these placentas. In growth-restricted pregnancies, the enzyme that converts creatine to phosphocreatine (the actual energy-storing form) was found to be roughly three times more active than in normal placentas, even though the gene was only slightly more expressed.¹⁰

At the same time, the raw building blocks of the creatine pathway were about 30% less abundant in growth-restricted placental tissue, while phosphocreatine was roughly twice as abundant. The growth-restricted placenta appears to be burning through its creatine supplies faster, converting everything it can into stored energy to compensate for its limited ability to generate ATP under low-oxygen conditions. When researchers blocked this creatine energy pathway experimentally, ATP levels dropped in growth-restricted placental tissue but not in normal tissue, confirming that the creatine circuit is critical specifically for placentas under stress.¹⁰

This finding is significant because it suggests creatine is not just a “nice to have” during complicated pregnancies; it may be an essential survival mechanism for stressed placentas. Whether supplementing the mother could support this pathway externally is an open question, but the biological rationale is compelling.

Maternal Creatine Levels and Birth Outcomes

While the interventional evidence in humans is thin, observational data offers some clues. A retrospective cohort study found that higher maternal urinary creatine concentration was positively associated with both birthweight and birth length. After adjusting for confounders, each unit increase in maternal urinary creatine was associated with a roughly 1.2-unit increase in birthweight percentile and a small but statistically significant increase in birth length.¹¹

This is observational data, so it cannot prove that having more creatine causes bigger babies. Women with higher creatine levels might also eat more protein, have better overall nutrition, or differ in other ways that affect fetal growth. Still, it adds to the biological plausibility argument: creatine status in the mother seems to track with at least some measures of fetal well-being.

The First Human Pharmacokinetic Trial

Until recently, everything known about creatine supplementation in pregnancy came from animal models or observational human data. That changed with the completion of the first dose-escalation pharmacokinetic trial in pregnant women. This small, open-label study compared how a single 5-gram dose of creatine monohydrate was processed in healthy non-pregnant women and pregnant women in the third trimester. The key finding was that pregnancy did not significantly alter how the body absorbed and processed creatine: peak plasma concentrations and the time to reach them were comparable between the two groups.¹²

In a second stage, eight pregnant women took 5 grams of creatine every eight hours for three days. Computer modeling predicted that dosing creatine three to four times daily at 5 grams per dose (similar to the regimens used in athletic supplementation) would achieve the target steady-state plasma concentration within about 72 hours. No major adverse events or side effects were reported, and fetal monitoring showed no concerns.¹²

This trial was designed to figure out dosing, not to test whether creatine actually improves outcomes. With only fifteen women total across both stages, it is far too small to draw safety conclusions. But it clears an important hurdle: it shows that a proper clinical trial in pregnant women is feasible, that the dosing math works, and that no red flags appeared in this initial group. Larger randomized controlled trials are the necessary next step.

Safety Data From Animal Studies

In the spiny mouse model, creatine supplementation during pregnancy did not change maternal body weight or body composition. The main physiological effects were increased creatine excretion in the urine, along with increased sodium and chloride excretion in the first few days of supplementation. The body’s own creatine-making machinery dialed down in response to the external supply, which is the expected feedback response, and creatine transporter activity in the kidney and brain also decreased.¹³ The overall conclusion was that supplementation had minimal impact on creatine balance in either pregnant or non-pregnant animals.

For context, creatine monohydrate has a strong safety record in the general adult population. It has been studied extensively in athletes and in various clinical populations for decades, and long-term use in healthy adults appears to be safe based on the accumulated evidence.⁵ But “safe in healthy adults” and “safe during pregnancy” are not the same claim. Pregnancy changes kidney function, blood volume, and fluid balance in ways that could theoretically alter how creatine is handled or what side effects emerge. The human trial data is simply too limited to say with confidence that it is safe for routine use during pregnancy.

Why Your Doctor Probably Will Not Recommend It Yet

If the animal data is so promising, why isn’t creatine already being offered to pregnant women at risk of birth complications? The answer comes down to the standard of evidence required before recommending any intervention in pregnancy. The threshold is intentionally high because both the mother and fetus are exposed, and unintended effects may not show up until years later.

Right now, the evidence sits at the “strong preclinical rationale with very early human data” stage. The spiny mouse studies are encouraging but cannot be directly extrapolated to humans. The sheep study raised a genuine question about whether maternal supplementation even delivers creatine to the fetus in all species. The one human pharmacokinetic trial showed feasibility and tolerability, but it was tiny and uncontrolled. No randomized controlled trial has yet tested whether creatine supplementation during pregnancy actually reduces rates of birth asphyxia injury, improves Apgar scores, or changes any clinical outcome that matters to parents and clinicians.

For a supplement to move into routine prenatal care, it typically needs at least one well-powered randomized trial showing a meaningful benefit, along with safety data from hundreds or thousands of pregnancies. Creatine is not there yet. That does not mean it will never get there, and researchers working in this space clearly believe the evidence is heading in a positive direction. But “promising preclinical data” has a long and humbling history of not translating into clinical practice.

Dietary Creatine During Pregnancy

Even without supplementation, you are already getting creatine from your diet if you eat animal products. Red meat and fish are the richest sources, with a typical omnivorous diet providing roughly 1 to 2 grams per day. Your body also synthesizes creatine from amino acids, primarily in the liver and kidneys. Vegetarians and vegans have lower baseline creatine stores because they lack dietary intake and depend entirely on endogenous synthesis.

This raises a question that has not been formally studied in pregnant populations: are vegetarian or vegan pregnant women at a disadvantage when it comes to creatine status? The metabolic data showing that urinary creatine drops in late pregnancy, suggesting the body is trying to conserve it, makes this a reasonable concern.² If demand is outstripping supply in women who eat meat, the deficit could theoretically be larger in women who do not. No study has yet compared pregnancy outcomes based on dietary creatine intake or endogenous creatine synthesis capacity, but it is an area worth watching.

For now, eating a balanced diet that includes protein-rich foods is the most evidence-supported way to maintain your creatine stores during pregnancy. If you are vegetarian or vegan, it may be worth discussing creatine status with your healthcare provider, though there are not yet any formal recommendations on this point. Supplementation remains in the “ask your doctor and understand that the data is early” category rather than the “well-established and recommended” category.

Supplement Quality and the Regulatory Gap

If you do decide to discuss creatine supplementation with your healthcare provider, one practical concern worth knowing about is product quality. Creatine monohydrate is sold as a dietary supplement, not a pharmaceutical, which means it is not subject to the same manufacturing and purity standards as prescription medications. Independent testing of commercial supplements has repeatedly found that some products contain contaminants, inaccurate doses, or unlisted ingredients. During pregnancy, when you are trying to minimize exposures to unknown substances, this is not a trivial concern.

If supplementation were ever recommended, the clinical trial used pharmaceutical-grade creatine monohydrate at defined doses with plasma-level monitoring. That level of quality control is very different from what you get with a tub of powder bought online. Anyone considering creatine in pregnancy should look for products that carry third-party certification from organizations that test for purity and label accuracy. Even then, the lack of pregnancy-specific safety data means you are making a decision with incomplete information, which is the honest framing your provider should give you.